Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without Mutations or Fusion.

Targeted therapies based on mutations or on the fusion oncogene have become the standard treatment for certain patients with lung adenocarcinoma (LUAD). However, most LUAD patients have no mutation or fusion, and their oncogenetic alterations remain to be characterized. Here we conducted an integrated analysis of public datasets to assess the genomic alterations of 23 highly lung cancer-associated genes. The copy numbers of these genes were measured in ten micro-dissected, paired tumors and normal lung tissues of LUAD patients without mutations or fusion. The copy numbers of , , , and were lower in tumors compared with those for normal tissues. Although there were reduced mRNA levels of and in tumors, there was a correlation between copy number and expression only for . In addition, analysis of the copy number alterations of these 23 genes revealed correlations between /, /, /, and / Our exploration of integrated copy number and gene expression analysis gives priority to the - and - pathways in developing therapeutic strategies for LUAD patients without mutations or fusion.